Astellas, Eisai To Double China Sales Forces To Meet Growing Demand
This article was originally published in PharmAsia News
Astellas Pharma and Eisai each has plans to double its sales force in China in an effort to meet a rising demand for drugs as the government expands insurance coverage
You may also be interested in...
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.